Coagulation factor Viia composition

The invention relates to pharmaceutical compositions for subcutaneous, intramuscular or intradermal administration of coagulation factor VIIa (FVIIa). The invention further relates to pharmaceutical compositions for prolonging the biological half-life of FVIIa in a mammal, preferably a human being by subcutaneous, intramuscular or intradermal injection. The invention also relates to a kit comprising FVIIa and a pharmaceutically acceptable carrier adapted for delivery of an effective dose of FVIIa to a patient in need thereof by subcutaneous, intramuscular or intradermal injection, a method of treatment of a disease affectable by FVIIIa, a method for prolonging the biological half-life of FVIIa in a mammal, and the use of FVIIa for the manufacture of said compositions. The invention relates to a pharmaceutical composition comprising Factor VIIa for subcutan, intramuscular or interdermal administration.Factor VIIa administered subcutanously, intramuscularly or intradermally shows a sufficient transport into the bloodstream in biologically active form and in adequate concentrations, and favorable pharmacokinetic properties.